SMAD3 and lung cancer: In line with this notion, both genetic deletion and pharmacologic inhibition of Smad3 resulted in enhanced N1 development of mouse bone marrow-derived neutrophils (BMDNs) stimulated with LLC cancer cell conditioned medium (LLC-CM) in vitro, arguing that Smad3 restricts TAN maturation in lung cancer (Fig. 4H and Supplementary Fig. 7).